Want to see IRD full AI Analyst Report?
IRD Stock Chart & Stats
$4.11
$0.16(5.48%)
At close: 4:00 PM EDT
$4.11
$0.16(5.48%)
Day’s Range― - ―
52-Week Range$1.70 - $7.07
Previous CloseN/A
Volume1.09M
Average Volume (3M)3.82M
Market Cap
$402.67M
Enterprise Value$405.18
Total Cash (Recent Filing)$88.81M
Total Debt (Recent Filing)$34.93M
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Nov 17, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.27
Shares Outstanding83,195,820
10 Day Avg. Volume2,138,194
30 Day Avg. Volume3,821,555
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)81.49
Price to Sales (P/S)88.10
P/FCF Ratio-35.48
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$13.08Price Target Upside218.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-1.05
Revenue Forecast (FY)$12.26M
Bulls Say, Bears Say
Bulls Say
Early Clinical Efficacy And SafetyEarly human data provide a meaningful foundation for the lead program: every participant showed improvement in at least one visual-function measure, while safety remained favorable. Replication in higher-dose cohorts could strengthen the asset’s clinical and commercial potential.
Clearer Regulatory Development PathFDA alignment reduces uncertainty around the evidence needed for a pivotal study and gives Opus a more defined development sequence. A clearer path to Phase 3 can improve execution focus, support partnership discussions, and create durable milestones for the lead therapy.
Expanded Addressable Patient OpportunityA larger estimated BEST1 patient population expands the potential market for OPGx-BEST1 beyond prior assumptions. Overenrollment in the next cohort also indicates the program can recruit continued clinical evidence, supporting broader development and future commercial opportunity.
Bears Say
Severe Ongoing LossesThe company remains deeply unprofitable, with operating and net losses far exceeding current revenue generation. This weak earnings profile limits internally funded investment and leaves successful clinical progress dependent on obtaining future financing or materially improving commercial economics.
Persistent Cash BurnSustained negative operating and free cash flow shows that current activities consume substantial cash rather than fund themselves. Continued burn can require repeated external capital, increasing dilution or financing pressure while the company advances expensive clinical and manufacturing programs.
Negative Equity And New DebtThe shift from positive equity and no debt to negative equity with substantial debt materially weakens financial flexibility. This structure can constrain future financing choices and heighten solvency pressure if losses and cash consumption persist through later-stage development.
Opus Genetics News
IRD FAQ
What was Opus Genetics’s price range in the past 12 months?
Opus Genetics lowest stock price was $1.70 and its highest was $7.07 in the past 12 months.
What is Opus Genetics’s market cap?
Opus Genetics’s market cap is $402.67M.
When is Opus Genetics’s upcoming earnings report date?
Opus Genetics’s upcoming earnings report date is Nov 17, 2026 which is in 46 days.
How were Opus Genetics’s earnings last quarter?
Opus Genetics released its earnings results on Aug 06, 2026. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.157 by $0.017.
Is Opus Genetics overvalued?
According to Wall Street analysts Opus Genetics’s price is currently Undervalued.
Does Opus Genetics pay dividends?
Opus Genetics does not currently pay dividends.
What is Opus Genetics’s EPS estimate?
Opus Genetics’s EPS estimate is -0.15.
How many shares outstanding does Opus Genetics have?
Opus Genetics has 83,195,820 shares outstanding.
What happened to Opus Genetics’s price movement after its last earnings report?
Opus Genetics reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.157. Following the earnings report the stock price went down -1.587%.
Which hedge fund is a major shareholder of Opus Genetics?
Currently, no hedge funds are holding shares in IRD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Opus Genetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.08 (218.33% Upside)
$13.08 (218.33% Upside)
Blogger Sentiment
Bullish
IRD Sentiment 92%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Decreased
By 2.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $86.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 2.0%
Last 30 Days ▲ 2.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
193.33%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
140.44%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Opus Genetics
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
IRD Stock 12 Month Forecast
Average Price Target
$13.08
▲(218.33% Upside)
Technical Analysis
Ownership Overview
15.13% Insiders
3.48% Mutual Funds
40.70% Other Institutional Investors
32.74% Public Companies and
Individual Investors